Holding Market Value ($) Weight (%) Star Rating Matt's Roth IRA: Cash 5,263 1.96 N/A Matt's Roth IRA: Abiomed ABMD 184 0.07 N/A Matt's Roth IRA: Alpine Dynamic Dividend AOD 1,134 0.42 Matt's Roth IRA: Biomarin Pharmaceuticals
We are no longer providing equity research on Abiomed . We provide broad coverage of more than 1,800 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
Abiomed reported strong fiscal second-quarter ..... largely consistent with our expectations. Abiomed remains on track to reach our full-year ..... continues to grow, which supports our view of Abiomed 's positive moat trend. We think there
Abiomed reported fiscal first-quarter performance ..... variance from quarter to quarter, we think Abiomed can still reach our full-year projections ..... nascent stage of the acute VAD market that Abiomed is still pioneering, we do not think the
unlikely to reach commercialization before 2017. Even though it will be several years before the PHP product is marketable, it nonetheless provides Thoratec with important entree to the acute VAD niche that is currently dominated by Abiomed .
On Wednesday, Abiomed ABMD released preliminary fourth-quarter ..... our positive moat trend rating for Abiomed . Although we do not believe the firm ..... yet, momentum continues to build for Abiomed with the U.S. release of Impella
and next-generation products, the firm could remain on a high growth trajectory for the long run.Thoratec aims to enter Abiomed 's acute VAD niche in the next few years, which could add another large, underpenetrated niche to its target market opportunity
turbulence on the regulatory front, Abiomed ABMD remained on track operationally ..... set as the CP gains traction in Abiomed 's key geographic market during ..... the quarter (19% of sales), Abiomed maintains a healthy financial position
Abiomed 's prospects largely rely on products ..... reasons, including new competitive entries. Abiomed has a lot on its plate, and the organization ..... fish in the large medical device market, Abiomed may find it difficult to expand its reach
trim our fair value estimate for Abiomed ABMD to $17 per share from $18. Because ..... increase the cost of doing business for Abiomed and any other firm that wants to ..... device, meaning some didn't think Abiomed should be forced to collect additional